Radiation Oncologist @MCWRadOnc specializing in brain, liver and prostate cancer. Proud father, NPS enthusiast, and Chicago transplant All tweets are my own.
Joined January 2019
- Tweets1.6K
- Following1.3K
- Followers800
- Likes5.2K
Michael W. Straza, MD/PhD retweeted
Thanks, Frank! I get so many calls from friends and family asking about focal therapy advertising. I’ve also personally salvaged more than 20 focal therapy failures, including one patient who now lives with a debilitating day-to-day outcome that would have been exceedingly unlikely in the absence of the focal therapy context.
That’s why I’m so invested in pushing back on misinformation and encouraging patients and clinicians to wait for randomized trial data before embracing the marketing narrative.
Michael W. Straza, MD/PhD retweeted
It’s time to revisit the value of nephrectomy for RCC and when it might actually be a better treatment.
#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%
Michael W. Straza, MD/PhD retweeted
Hence why people don’t trust science or MDs anymore. We have a doctor you posted likely paid saying they violated national guidelines for what payers deem experimental, we have biomedical news agencies funded by industry saying these devices are amazing for things they are not approved for, we have major medical meetings promoting these devices, we even have @nytimes articles saying how great these devices are.
Yet reality is there is not a single well done multi center randomized trial with reasonable endpoints and good followup showing it is better than AS or RT.
To be clear, none of this is targeting the Vanquish system. It is the whole field of ablative devices being used for cancer without being approved for cancer.
Michael W. Straza, MD/PhD retweeted
As if on cue:
redjournal.org/article/S0360…
@RonaldChenMD
Michael W. Straza, MD/PhD retweeted
Riegel et al. @BrittaBureauMD @MedicalCollege analyzed real-world outcomes for newly diagnosed GBM patients treated with or without TTFields and found that TTFields improved OS and PFS, with higher device usage linked to better outcomes. #JNO
Read more:link.springer.com/article/10…
Michael W. Straza, MD/PhD retweeted
Congratulations to Dr. @whallradonc on being named the next Chair for @MCWRadOnc! We are so fortunate to have him as our next leader. I look forward to working with him to advance @MedicalCollege and @MCWCancerCenter's impact in cancer care and beyond.
Michael W. Straza, MD/PhD retweeted
Our comprehensive assessment of NCI cooperative group trials is out in @JNCI_Now!
If you are involved or enrolling in coop trials, please consider reading.
A 🧵of our major findings. 1/12
academic.oup.com/jnci/advanc…
Michael W. Straza, MD/PhD retweeted
"What is 'too old' for spine SBRT re: risk of vertebral compression fracture (VCF)?" is something colleagues and I debated at tumor boards on many occasions. We now have the answer (OPEN access) @IJROBP @UofTDRO @SahgalArjun #radonc #SBRT
sciencedirect.com/science/ar…
1/x
Michael W. Straza, MD/PhD retweeted
The NRG-BN013 phase III clinical trial was recently activated as a part of the NRG Oncology brain tumor portfolio. NRG-BN013 will compare two schedules of stereotactic radiosurgery (SRS) for patients with intact brain metastases. @Rrkotecha Read more: ow.ly/7Paq50Tmfma
Michael W. Straza, MD/PhD retweeted
Our annual Technical and Clinical Abstract Awards will now honour two of our most dedicated colleagues.
🔬 The Technical Abstract Award is named after Prof. Jan Jacob Wouter Lagendijk
🏥 The Clinical Abstract Award is named after Dr. Christopher Schultz
mrlconsortium.org
Michael W. Straza, MD/PhD retweeted
Excited to be open to accrual! Lucky number NRG BN013 - a phase 3 randomized trial of SRS vs. FSRS for intact brain mets @NRGonc @JYangMDPhD @MartinTomMD @BrainTumorDoc @DrVogelbaum @MeiPolley
Michael W. Straza, MD/PhD retweeted
⚡️Today FDA approved Vorasidenib for IDH-mutant low grade gliomas
When patients ask you about this drug, make sure to inform them that
▶️ risk of tumor progression at 2 years is 49% with Vorasidenib (INDIGO trial) compared to 15% with chemoRT (RTOG 9802)
▶️tumors remain stable without any major progression in 83% of patients receiving Vorasidenib versus 88% receiving a sugar pill (INDIGO trial, Table S4)
▶️patients who do not receive standard chemoRT live 5.5 years shorter than those who do (RTOG 9802)
▶️Vorasidenib has never been compared to standard chemoRT in a rigorous clinical trial
#BreakingNews Today, the U.S. FDA approved the first targeted therapy for Grade 2 IDH-mutant #glioma – a relentless condition that hasn’t seen treatment advances in nearly 25 years. Learn more about this and Servier’s commitment to patients: ow.ly/yN8j50SRETU
Michael W. Straza, MD/PhD retweeted
Just over 2 weeks away from Strain for the Brain, annual run/walk to support brain tumor patients and their families as well as brain tumor research @MCWCancerCenter @MCWBrain_Spine @NeurologyMCW @MCWNeurosurgery. Sign up today! StrainForTheBrain.org
Michael W. Straza, MD/PhD retweeted
Wild, but true:
With Giannis and Damian Lillard out, the Bucks become the first team EVER to win a playoff game without their top-2 scorers from the regular season. H/t @StatsWilliams
